Novozymes Biopharma has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, CA. Novozymes will supply its recombinant human albumin, Recombumin, for use in the development of a new GLP-1 analog in Phase II trials for Type 2 diabetes. The use of Recombumin has the potential to significantly reduce dosing frequency, allowing patients to self-inject once per week instead of once or twice daily. “This supply agreement is a great example of using Novozymes’ Recombumin as a veh...